Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study
di
M. Gharbiya, F. Allievi, S. Conflitti, M. Esposito, V. Scavella, A. Moramarco, F. Cruciani
Purpose. To evaluate the effi cacy and safety of intravitreal bevacizumab for the treatment of myopic choroidal neovascularization (CNV). Design. Prospective, non-randomized, interventional clinical study. Methods. Twenty eyes from 20 patients with CNV secondary to pathologic myopia participated in this study. These patients had already completed 12 months of follow-up. All patients were scheduled for 3 monthly intravitreal bevacizumab 1.25 mg injections. ETDRS bestcorrected visual acuity (BCVA), foveal center thickness (FCT) on OCT and CNV size as assessed by fl uorescein angiography were examined before and after treatment. Patients were followed up for 24 months. Results. Mean BCVA (± SD) at baseline was 24.8 (± 11.86) letters (Snellen equivalent: 20/80). At 24 months after treatment the mean BCVA (± SD) improved signifi cantly (p less than 0.05) to 44 (± 13.99) letters (Snellen equivalent: 20/33). At 24 month follow-up, BCVA improved of 10 letters or more in 17 (85%) out of 20 treated eyes and improved of 15 letters or more in 15 (75%) eyes. No treated eyes experienced a worsening of BCVA from baseline. Mean foveal center thickness (FCT) (± SD) at baseline was 223 (± 47,43) microns. By month 24, mean FCT (±SD) reduced to 190 (± 29.01) microns (p less than 0.05). Mean area of the CNVs at baseline was 0.77 (± 0.78) mm2, which decreased to 0.31 ± (0.51) mm2 and 0.30 (± 0.50) mm2 at 12 (p less than 0.05) and 24 months (p<0.05), respectively. At 24 months follow-up absence of fl uorescein leakage from the CNV was demonstrated in 18 (90%) out of 20 treated eyes. No ocular or systemic adverse effects from treatment were encountered. Conclusion. Eyes with myopic CNV treated with intravitreal bevacizumab over 2 years had signifi cant anatomic and functional improvement. Further studies will be needed to confi rm the long-term effi cacy and safety of this treatment. Clin Ter 2010; 161(3):e87-e93
ATTENZIONE: per accedere al servizio
di consultazione online dei file pdf occorre essere
abbonati alla rivista ed aver abilitato il propriopin.
Se non siete ancora abbonati potete abbonarvi e ricevere il pin attraverso
il nostro online
store.
Per l'attivazione del pin ricevuto, contattare ordini@seu-roma.it.
